You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Automated Monitoring of Chemotactic Cell Movement

    SBC: APPLIED BIOPHYSICS, INC.            Topic: N/A

    DESCRIPTION ( provided by applicant): The ECIS/taxis technology can detect cells that move to a small electrode through an agarose matrix by the resistance that they impart to an electrical circuit as they cover parts of the small electrode. This system is amenable to rapid throughput analysis of cell behavior in the presence of chemokines and other agents that ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  2. Automated Monitoring of Chemotactic Cell Movement

    SBC: APPLIED BIOPHYSICS, INC.            Topic: N/A

    DESCRIPTION ( provided by applicant): The ECIS/taxis technology can detect cells that move to a small electrode through an agarose matrix by the resistance that they impart to an electrical circuit as they cover parts of the small electrode. This system is amenable to rapid throughput analysis of cell behavior in the presence of chemokines and other agents that ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  3. COMPUTERIZED STEREOCAMPIMETER TO MEASURE CENTRAL SCOTOMA

    SBC: OPTICOLOGY, INC.            Topic: N/A

    The proposed research intends to design and build an instrument of accurately measure centrally located pathological areas of non-vision, or central scotomas, within the 30 to 60 degrees field of vision. The new device is intended to serve as a supplement to commercially available automatic perimeters, which are known to be inaccurate when retinal defects are confined to the central field of visi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. Combined Gene Therapy/Tissue Engineered Cartilage Repair

    SBC: TISSUEGENESIS, INC.            Topic: N/A

    DESCRIPTION (Verbatim from Applicant): The objective of this Phase I protocol is to develop a novel approach for the repair of articular cartilage using gene enhanced tissue engineering (GETE). Successful clinical repair of articular cartilage continues to be elusive. The current study seeks to repair articular cartilage defects using constructs containing cultured perio ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Orally available transition state inhibitors for triple negative breast cancer

    SBC: NANOMETICS LLC            Topic: NCI

    Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

    SBC: CUREFAKTOR PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Modified RNA tools and diagnostics for drug abuse

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government